Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Gibson

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
The American Journal of Cardiology|January 7, 1998
Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flowC M Gibson, J T Dodge, M Goel, et al.
American Heart Journal|May 29, 1999
Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study GroupC M Gibson, K A Ryan, M Kelley, et al.
Journal of Thrombosis and Haemostasis : JTH|August 2, 2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysisG Chi, S Z Goldhaber, J M Kittelson, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
European Heart Journal|June 19, 2002
Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-IIE M Antman, H A Cooper, C M Gibson, et al.
The New England Journal of Medicine|June 23, 2001
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofibanC P Cannon, W S Weintraub, L A Demopoulos, et al.
Journal of the American College of Cardiology|December 19, 1998
Mechanical debulking versus balloon angioplasty for the treatment of true bifurcation lesionsH L Dauerman, P J Higgins, A M Sparano, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
The American Journal of Cardiology|September 8, 2001
Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapyJ A de Lemos, D A Morrow, C M Gibson, et al.
Circulation|December 6, 2001
Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) studyK W Baran, M Nguyen, G R McKendall, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
The American Journal of Cardiology|January 7, 1998
Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flowC M Gibson, J T Dodge, M Goel, et al.
American Heart Journal|May 29, 1999
Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study GroupC M Gibson, K A Ryan, M Kelley, et al.
Journal of Thrombosis and Haemostasis : JTH|August 2, 2017
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysisG Chi, S Z Goldhaber, J M Kittelson, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
European Heart Journal|June 19, 2002
Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-IIE M Antman, H A Cooper, C M Gibson, et al.
The New England Journal of Medicine|June 23, 2001
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofibanC P Cannon, W S Weintraub, L A Demopoulos, et al.
Journal of the American College of Cardiology|December 19, 1998
Mechanical debulking versus balloon angioplasty for the treatment of true bifurcation lesionsH L Dauerman, P J Higgins, A M Sparano, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
The American Journal of Cardiology|September 8, 2001
Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapyJ A de Lemos, D A Morrow, C M Gibson, et al.
Circulation|December 6, 2001
Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) studyK W Baran, M Nguyen, G R McKendall, et al.
Pageof 10